Iradimed Corporation ranks 79th in TIME's America's Growth Leaders for 2026, recognizing its exceptional revenue and stock performance.
Quiver AI Summary
IRADIMED CORPORATION, based in Orlando, Florida, announced its inclusion in TIME's list of America's Growth Leaders for 2026, ranking 79th among 501 top U.S. companies noted for exceptional growth. The recognition is based on a thorough evaluation by TIME and Statista, focusing on revenue growth, financial stability, and stock performance. IRADIMED, a leader in developing MRI-compatible medical devices, has achieved consistent revenue growth with 17 consecutive quarters of record revenue. CEO Roger Susi emphasized the company's commitment to innovation and operational excellence. The firm specializes in non-magnetic intravenous infusion pumps and vital signs monitoring systems designed for safe use during MRI procedures. For more information, visit their website.
Potential Positives
- IRADIMED CORPORATION has been recognized on TIME's prestigious list of America's Growth Leaders for 2026, ranking 79th among top U.S. companies demonstrating outstanding growth.
- This recognition highlights the company's consistent revenue growth, evidenced by 17 consecutive quarters of record revenue, reflecting successful operational strategies in the MRI-compatible medical device market.
- The accolade from TIME and Statista underscores IRADIMED's financial stability and stock performance, reinforcing investor confidence and the company's reputation in the medical device industry.
Potential Negatives
- While being named to TIME's America's Growth Leaders list is an achievement, it may highlight increasing scrutiny regarding future performance expectations, with potential pressure on the company to maintain growth amidst changing market conditions.
- The mention of a rigorous and data-driven evaluation methodology raises implications that any drop in future rankings could lead to negative perceptions about the company's stability and growth trajectory.
- The focus on consistent revenue growth over 17 consecutive quarters may underscore the importance of sustaining this momentum, indicating that any disruption in performance could raise concerns among investors and stakeholders.
FAQ
What recognition did Iradimed Corporation receive in 2026?
Iradimed was named to TIME's list of America's Growth Leaders for 2026, ranking 79th among U.S. companies.
How did TIME determine the Growth Leaders ranking?
The ranking evaluated companies based on Revenue Growth, Financial Stability, and Stock Performance, using a comprehensive scoring model.
Why is Iradimed significant in the MRI medical device market?
Iradimed is the only provider of a non-magnetic IV infusion pump designed specifically for safe operation during MRI procedures.
What is the MRidium® system?
MRidium® is an MRI-compatible IV infusion pump that safely delivers fluids during MRI scans using non-magnetic technology.
How does the Iradimed 3880 monitoring system enhance patient safety?
The Iradimed 3880 vital signs monitor operates in high magnetic fields, allowing continuous monitoring of critically ill patients during MRI scans.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IRMD Insider Trading Activity
$IRMD insiders have traded $IRMD stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $IRMD stock by insiders over the last 6 months:
- ROGER E. SUSI (CEO, PRESIDENT, CHAIRMAN) has made 0 purchases and 19 sales selling 35,000 shares for an estimated $2,609,962.
- MONTY K ALLEN sold 1,102 shares for an estimated $76,148
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IRMD Hedge Fund Activity
We have seen 77 institutional investors add shares of $IRMD stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RANGER INVESTMENT MANAGEMENT, L.P. removed 95,220 shares (-44.3%) from their portfolio in Q3 2025, for an estimated $6,775,855
- MILLENNIUM MANAGEMENT LLC added 41,481 shares (+59.1%) to their portfolio in Q2 2025, for an estimated $2,480,148
- UNIPLAN INVESTMENT COUNSEL, INC. added 31,620 shares (+64.9%) to their portfolio in Q2 2025, for an estimated $1,890,559
- GOLDMAN SACHS GROUP INC removed 25,685 shares (-15.2%) from their portfolio in Q2 2025, for an estimated $1,535,706
- POLEN CAPITAL MANAGEMENT LLC added 24,889 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,488,113
- COPELAND CAPITAL MANAGEMENT, LLC removed 24,419 shares (-5.3%) from their portfolio in Q3 2025, for an estimated $1,737,656
- TUDOR INVESTMENT CORP ET AL removed 23,467 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,403,091
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ORLANDO, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative magnetic resonance imaging (MRI)-compatible medical devices, today announced its selection to TIME's prestigious list of America's Growth Leaders for 2026. This marks the Company's recognition among the top U.S. companies demonstrating outstanding growth, as determined by TIME and Statista.
The ranking evaluated thousands of public companies across three key dimensions: Revenue Growth, Financial, and Stock Performance. Scores from these dimensions were weighted equally in a comprehensive model, with the highest-scoring 501 companies earning the distinction of "America's Growth Leaders of 2026.” Iradimed ranked 79th on the list.
“We are honored to be named to TIME's America's Growth Leaders for 2026,” said Roger Susi, President and Chief Executive Officer of Iradimed. “This recognition reflects our team's relentless commitment to innovation, operational excellence, and delivering long-term shareholder return. Our consistent revenue growth—highlighted by 17 consecutive quarters of record revenue—along with strong financial health and stock performance, underscores the success of our strategy in the MRI-compatible medical device market. We extend our deepest gratitude to our employees for their hard work and dedication, and to our shareholders for their continued support.”
For more information and the complete list, visit: https://time.com/7327022/americas-growth-leaders-2025/ .
About the Methodology
TIME and Statista evaluated U.S.-based public companies using a rigorous, data-driven approach across three equally weighted dimensions:
- Revenue Growth : Focused on compound annual growth rate (CAGR) from 2021 to 2024, with a minimum revenue threshold.
- Financial Stability: Analyzed profitability alongside classic metrics such as the Piotroski F-Score and Altman Z-Score.
-
Stock Performance:
Assessed using multiple KPIs, including average annual growth rate, recent returns, comparison to the overall market, and volatility over the past five years.
Data was consolidated into a scoring model with a maximum of 100 points. The 501 companies with the highest scores were named America's Growth Leaders of 2026.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for safe use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system features an easy-to-use design and enables effective communication of patient vital signs information to clinicians.
For more information, please visit www.iradimed.com .
Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022